Consortium Partners

PrintFriendly and PDF
  • Consortium as a whole

The identification of biomarkers and endpoints relevant for alternative testing of repeated dose toxicity requires a multidisciplinary approach bringing together complementary expertise and research resources in the fields of alternative testing, toxicology, liver, heart and kidney cell culture, including of stem cell-derived cells (human ES and iPS cells), various measurement techniques such as imaging, impedance measurement, electrical activity, metabonomics, toxicogenomics, epigenetics, proteomics, statistics and modelling, bioinformatics and project management.

The DETECTIVE consortium brings together 15 partners from 8 different European countries which have been carefully selected to bring particular expertise and/or facilities into the project.

  • Coordinator

Jürgen Hescheler

University Hospital of Cologne (UKK)
Institute of Neurophysiology
Robert-Koch-Str. 39
Köln 50931, Germany
E-mail :

  • Partners

JRC – Joint Research Centre
Universiteit Maastricht
Roche Diagnostics GmbH
Vrije Universiteit Brussel
ProteoSys AG
Forschungsgesellschaft für Arbeitsphysiologie und Arbeitschutz e.V.
Imperial College
Deutsches Krebsforschungszentrum
OÜ Quretec
Medizinische Unviversität Innsbruck
Leibnitz-Institut für Analytische Wissenschaften – ISAS – e.V.
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V.
Universiteit Leiden

  • Advisory Board

The DETECTIVE Advisory Board, which interact with the “Knowledge management” (WP1), is currently composed of 3 external experts who will provide advice and make proposals for decisions on specific research issues.

Thomas Steger-Hartmann, Bayer Schering

Andrew White, Cosmetics Europe

Thomas Broschard, Institute of Toxicology of Merck